- In December 2024, AbbVie Inc. announced positive topline results from its pivotal Phase III TEMPO-2 trial evaluating tavapadon, a first-in-class D1/D5 partial dopamine agonist, as a flexible-dose monotherapy for early Parkinson’s disease. Tavapadon is being investigated as a once-daily treatment, potentially offering a novel approach to PD management
- In October 2024, Supernus Pharmaceuticals has received FDA approval for ONAPGO, a continuous subcutaneous infusion device delivering apomorphine hydrochloride. This device is designed to manage motor fluctuations in adults with advanced Parkinson’s disease
- In May 2021, AffaMed Therapeutics announced that China's National Medical Products Administration (NMPA) has approved the Clinical Trial Application (CTA) for a Phase IIb global clinical trial led by AffaMed, to evaluate the safety and efficacy of AM006 in patients with early Parkinson’s Disease (PD)
- In January 2019, Ligand Pharmaceuticals Incorporated partner with Seelos Therapeutics, Inc. The companies will focus on the development and commercialization of central nervous system (CNS) therapeutics including dopamine agonists with known mechanisms of action in areas with high unmet medical need
